Gossamer Bio Publishes TORREY Phase 2 Results in The Lancet Respiratory Medicine

SAN DIEGO-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company centered on the development and commercialization of seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has announced a significant milestone. The company's TORREY Phase 2 study manuscript has been published in the prestigious Lancet Respiratory Medicine journal. The study, formally titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY): A Randomized, Double-blind, Placebo-controlled Phase 2 Trial," offers critical insights into the advancement of PAH treatments.

The TORREY study was a Phase 2, randomized, multicenter, multinational, double-blind, placebo-controlled trial aimed at assessing the efficacy and safety of Gossamer's novel therapeutic candidate, seralutinib, in managing PAH. PAH is a progressive and potentially fatal condition that can lead to right heart failure, significantly reducing the quality of life for those affected. In the study, 86 patients were randomized to receive either seralutinib or a placebo via dry powder inhaler twice daily over a 24-week period. The results showed a statistically significant improvement in the primary endpoint, reduction of pulmonary vascular resistance (PVR), as well as in other critical measures of disease, including evaluations of right heart structure and function.

Following the promising results from TORREY, seralutinib has been advanced into the ongoing global Phase 3 PROSERA Study. This study aims to further assess the treatment's efficacy in WHO Functional Class II and III PAH patients. The progression to Phase 3 signifies confidence in seralutinib's potential to fundamentally improve patient outcomes in PAH treatment.

Faheem Hasnain, CEO, Co-founder, and Chairman of Gossamer Bio, emphasized the importance of the publication, stating, "The publication of the TORREY results in Lancet Respiratory Medicine represents a significant milestone in our ongoing commitment to addressing unmet medical needs for patients with pulmonary hypertension. The results detailed in the publication help to form the basis of our excitement for the potential of seralutinib to improve the lives of patients living with this progressive disease."

The study's manuscript is accessible and will be highlighted in an upcoming print edition of the Lancet Respiratory Medicine journal. This publication not only validates the scientific rigour behind Gossamer’s research but also enhances the visibility of seralutinib within the scientific community and among healthcare providers.

Gossamer Bio remains dedicated to becoming a leader in the biopharmaceutical industry, particularly in the field of pulmonary hypertension. The company aims to transform the lives of patients suffering from this complex and challenging condition through innovative treatments like seralutinib.

With the progression of seralutinib into Phase 3 trials and its recognition in a leading medical journal, Gossamer Bio continues to make strides towards providing a viable therapeutic option for PAH patients. These developments underscore the company's commitment to addressing significant medical needs and improving patient health outcomes in the realm of pulmonary hypertension.